Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial

Inflamm Bowel Dis. 2010 May;16(5):731-3. doi: 10.1002/ibd.21080.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Colitis, Ulcerative / drug therapy*
  • Double-Blind Method
  • Drug Resistance*
  • Female
  • Heptanoates / therapeutic use*
  • Humans
  • Male
  • Mesalamine / therapeutic use*
  • Middle Aged
  • Placebos
  • Receptors, Prostaglandin E / agonists*
  • Receptors, Prostaglandin E, EP4 Subtype
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Heptanoates
  • ONO4819
  • PTGER4 protein, human
  • Placebos
  • Receptors, Prostaglandin E
  • Receptors, Prostaglandin E, EP4 Subtype
  • Mesalamine